Entrada Therapeutics Inc
Follow $TRDA
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $TRDA by emailVeridion Score
BETALOW CONF · 4 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is TRDA moving today?
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
TRDA overview
Related filings and maps
Congress activity in TRDA
No receipt-qualified Congressional disclosure is present for TRDA in the cached public ledger.
TRDA contract awards, year to date.
Public federal awards linked to this ticker.
TRDA lobbying filings, year to date.
Registered lobbying filings matched to Entrada Therapeutics Inc.